Table 2.
Mean Incidence Rates and Rate Ratios as a Function of Estimated Asymmetric Propensity Score Percentiles From 1,000 Simulated Data Sets in the Presence of Unmeasured Confounding Due to “Last Resort Treatment” and “Treatment Withheld”
PS “Percentile”a | Treatment Prevalence = 0.2 |
Treatment Prevalence = 0.05 |
||||||||
Treated |
Untreated |
RRb | Treated |
Untreated |
RRb | |||||
No. | IRc | No. | IRc | No. | IRc | No. | IRc | |||
“Last resort treatment” | ||||||||||
<0d | 63 | 11 | 261 | 12 | ||||||
0–1 | 19 | 133 | 561 | 22 | 6.68 | 4 | 117 | 635 | 24 | 5.51 |
1–2.5 | 29 | 188 | 528 | 34 | 5.85 | 7 | 181 | 685 | 38 | 5.07 |
2.5–5 | 49 | 219 | 659 | 45 | 5.04 | 12 | 244 | 771 | 53 | 4.75 |
5–25 | 18 | 207 | 201 | 52 | 4.58 | 3 | 231 | 117 | 59 | 4.68 |
25–50 | 242 | 160 | 2,007 | 67 | 2.40 | 62 | 287 | 2,283 | 81 | 3.56 |
50–75 | 451 | 221 | 2,010 | 108 | 2.06 | 112 | 259 | 2,376 | 120 | 2.17 |
75–95 | 719 | 360 | 1,608 | 172 | 2.10 | 182 | 399 | 1,901 | 190 | 2.10 |
95–97.5 | 163 | 514 | 201 | 256 | 2.06 | 42 | 579 | 238 | 282 | 2.09 |
97.5–99 | 129 | 607 | 121 | 301 | 2.10 | 34 | 673 | 143 | 335 | 2.06 |
99–100 | 137 | 834 | 80 | 406 | 2.14 | 36 | 949 | 95 | 455 | 2.15 |
>100d | 5 | 1,679 | 1 | 1,772 | ||||||
“Treatment withheld” | ||||||||||
<0d | 91 | 6 | 321 | 10 | ||||||
0–1 | 19 | 33 | 718 | 15 | 2.48 | 4 | 39 | 705 | 19 | 2.08 |
1–2.5 | 29 | 54 | 601 | 27 | 2.18 | 7 | 66 | 712 | 32 | 2.13 |
2.5–5 | 49 | 79 | 683 | 40 | 2.06 | 12 | 96 | 813 | 47 | 2.12 |
5–25 | 2 | 99 | 19 | 44 | 2.54 | 1 | 97 | 44 | 48 | 2.30 |
25–50 | 239 | 136 | 1,914 | 66 | 2.07 | 57 | 151 | 2,160 | 74 | 2.06 |
50–75 | 474 | 222 | 2,014 | 108 | 2.06 | 117 | 242 | 2,378 | 119 | 2.04 |
75–95 | 767 | 367 | 1,611 | 183 | 2.01 | 188 | 408 | 1,903 | 233 | 1.76 |
95–97.5 | 160 | 591 | 201 | 554 | 1.10 | 41 | 618 | 238 | 526 | 1.20 |
97.5–99 | 114 | 830 | 121 | 1,058 | 0.81 | 31 | 777 | 143 | 803 | 1.00 |
99–100 | 92 | 1,623 | 80 | 2,348 | 0.71 | 29 | 1,296 | 95 | 1,673 | 0.80 |
>100d | 2 | 5,662 | 1 | 4,726 | ||||||
“Last resort treatment” and “treatment withheld” | ||||||||||
<0d | 61 | 11 | 261 | 12 | ||||||
0–1 | 19 | 125 | 550 | 21 | 6.75 | 5 | 103 | 627 | 22 | 5.25 |
1–2.5 | 29 | 173 | 516 | 31 | 5.99 | 7 | 159 | 651 | 35 | 4.87 |
2.5–5 | 49 | 199 | 650 | 41 | 5.01 | 12 | 219 | 754 | 49 | 4.65 |
5–25 | 21 | 200 | 238 | 48 | 4.84 | 3 | 238 | 150 | 55 | 4.75 |
25–50 | 248 | 148 | 2,013 | 64 | 2.35 | 65 | 261 | 2,308 | 77 | 3.44 |
50–75 | 466 | 212 | 2,013 | 104 | 2.05 | 117 | 241 | 2,375 | 114 | 2.12 |
75–95 | 752 | 349 | 1,611 | 173 | 2.03 | 188 | 389 | 1,900 | 222 | 1.76 |
95–97.5 | 158 | 562 | 201 | 500 | 1.16 | 41 | 591 | 238 | 500 | 1.21 |
97.5–99 | 112 | 778 | 121 | 978 | 0.82 | 31 | 742 | 143 | 760 | 1.01 |
99–100 | 91 | 1,518 | 80 | 2,197 | 0.71 | 29 | 1,236 | 95 | 1,592 | 0.80 |
>100d | 2 | 5,219 | 1 | 4,170 |
Abbreviations: IR, incidence rate; PS, propensity score; RR, rate ratio.
Asymmetric PS percentiles according to PS distribution in treated and untreated persons separately (to allow closer assessment of persons treated contrary to prediction). Percentiles between 0 and 5 are derived from the PS distribution in the treated patients; all other percentiles are derived from the PS distribution in the untreated patients.
Controlled for measured covariates based on PS stratification; inconsistencies with the incidence rates in the treated and untreated are due to rounding.
Per 1,000 person-years (repeated events).
Untreated patients in the <0 asymmetric PS percentile stratum are those with a lower PS than the lowest one observed in the treated patients (nonoverlap). Treated patients in the >100 asymmetric PS percentile stratum are those with a higher PS than the highest one observed in the untreated patients (nonoverlap).